Diagnosis and treatment of latent tuberculosis in patients with multiple sclerosis, expert consensus. On behalf of the Colombian Association of Neurology, Committee of Multiple Sclerosis

Background: Multiple sclerosis is an inflammatory and neurodegenerative demyelinating disease. Current treatment of multiple sclerosis focuses on the use of immunomodulatory, immunosuppressant, and selective immunosuppressant agents. Some of these medications may result in high risk of opportunistic...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2018
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/24625
Acceso en línea:
https://doi.org/10.1177/2055217317752202
https://repository.urosario.edu.co/handle/10336/24625
Palabra clave:
Medical and Health Sciences
Clinical Sciences
Rights
License
Abierto (Texto Completo)
id EDOCUR2_1989bc17e13602cf7cdd5d77356432d8
oai_identifier_str oai:repository.urosario.edu.co:10336/24625
network_acronym_str EDOCUR2
network_name_str Repositorio EdocUR - U. Rosario
repository_id_str
spelling 3503d98b-87a6-4b47-8bfb-4acd1262e576-1193a5fdf-7195-4129-8398-3ef88ab2f369-10b96d002-3992-4ee1-8e90-e714a33c4e06-113bbdf66-c55d-4f9b-a6c0-aa1b900a9bb2-17ac36ac9-946b-40e6-8dd8-4012a9cea09e-109397e82-4de9-44ae-af1a-28e2608c9ccb-16379ef1c-371d-4a92-b2e7-4a74deaa9dff-179943239600799479176002020-06-11T13:20:54Z2020-06-11T13:20:54Z2018-01Background: Multiple sclerosis is an inflammatory and neurodegenerative demyelinating disease. Current treatment of multiple sclerosis focuses on the use of immunomodulatory, immunosuppressant, and selective immunosuppressant agents. Some of these medications may result in high risk of opportunistic infections including tuberculosis.Objective: The purpose of this study was to obtain consensus from a panel of neurologists, pulmonologists, infectious disease specialists, and epidemiology experts regarding the diagnosis, treatment, and monitoring of latent tuberculosis in patients with multiple sclerosis.Methods: A panel of experts in multiple sclerosis and tuberculosis was established. The methodological process was performed in three phases: definition of questions, answer using Delphi methodology, and the discussion of questions not agreed.Results: Tuberculosis screening is suggested when multiple sclerosis drugs are prescribed. The recommended tests for latent tuberculosis are tuberculin and interferon gamma release test. When an anti-tuberculosis treatment is indicated, monitoring should be performed to determine liver enzyme values with consideration of age as well as comorbid conditions such as a history of alcoholism, age, obesity, concomitant hepatotoxic drugs, and history of liver disease.Conclusion: Latent tuberculosis should be considered in patients with multiple sclerosis who are going to be treated with immunomodulatory and immunosuppressant medications. Transaminase level monitoring is required on a periodic basis depending on clinical and laboratory characteristics. In addition to the liver impairment, other side effects should be considered when Isoniazid is prescribed.application/pdfhttps://doi.org/10.1177/2055217317752202https://repository.urosario.edu.co/handle/10336/24625engMultiple Sclerosis Journal - Experimental Translational and ClinicalNo. 1Multiple Sclerosis Journal - Experimental Translational and ClinicalVol. 4Multiple Sclerosis Journal - Experimental Translational and Clinical, ISSN: , Vol.4, No.1 (2018-01); pp. 2055217317752202https://journals.sagepub.com/doi/pdf/10.1177/2055217317752202Abierto (Texto Completo)http://purl.org/coar/access_right/c_abf2instname:Universidad del Rosarioreponame:Repositorio Institucional EdocURMedical and Health SciencesClinical SciencesDiagnosis and treatment of latent tuberculosis in patients with multiple sclerosis, expert consensus. On behalf of the Colombian Association of Neurology, Committee of Multiple SclerosisarticleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Navas, CarlosTorres-Duque, Carlos AMunoz-Ceron, JoeGarcía, Juan RZarco, LuisVélez, Lázaro AAwad, CarlosAlvarez, Carlos E.Castro, Carlos10336/24625oai:repository.urosario.edu.co:10336/246252021-06-03 00:50:31.248https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co
dc.title.spa.fl_str_mv Diagnosis and treatment of latent tuberculosis in patients with multiple sclerosis, expert consensus. On behalf of the Colombian Association of Neurology, Committee of Multiple Sclerosis
title Diagnosis and treatment of latent tuberculosis in patients with multiple sclerosis, expert consensus. On behalf of the Colombian Association of Neurology, Committee of Multiple Sclerosis
spellingShingle Diagnosis and treatment of latent tuberculosis in patients with multiple sclerosis, expert consensus. On behalf of the Colombian Association of Neurology, Committee of Multiple Sclerosis
Medical and Health Sciences
Clinical Sciences
title_short Diagnosis and treatment of latent tuberculosis in patients with multiple sclerosis, expert consensus. On behalf of the Colombian Association of Neurology, Committee of Multiple Sclerosis
title_full Diagnosis and treatment of latent tuberculosis in patients with multiple sclerosis, expert consensus. On behalf of the Colombian Association of Neurology, Committee of Multiple Sclerosis
title_fullStr Diagnosis and treatment of latent tuberculosis in patients with multiple sclerosis, expert consensus. On behalf of the Colombian Association of Neurology, Committee of Multiple Sclerosis
title_full_unstemmed Diagnosis and treatment of latent tuberculosis in patients with multiple sclerosis, expert consensus. On behalf of the Colombian Association of Neurology, Committee of Multiple Sclerosis
title_sort Diagnosis and treatment of latent tuberculosis in patients with multiple sclerosis, expert consensus. On behalf of the Colombian Association of Neurology, Committee of Multiple Sclerosis
dc.subject.keyword.spa.fl_str_mv Medical and Health Sciences
Clinical Sciences
topic Medical and Health Sciences
Clinical Sciences
description Background: Multiple sclerosis is an inflammatory and neurodegenerative demyelinating disease. Current treatment of multiple sclerosis focuses on the use of immunomodulatory, immunosuppressant, and selective immunosuppressant agents. Some of these medications may result in high risk of opportunistic infections including tuberculosis.Objective: The purpose of this study was to obtain consensus from a panel of neurologists, pulmonologists, infectious disease specialists, and epidemiology experts regarding the diagnosis, treatment, and monitoring of latent tuberculosis in patients with multiple sclerosis.Methods: A panel of experts in multiple sclerosis and tuberculosis was established. The methodological process was performed in three phases: definition of questions, answer using Delphi methodology, and the discussion of questions not agreed.Results: Tuberculosis screening is suggested when multiple sclerosis drugs are prescribed. The recommended tests for latent tuberculosis are tuberculin and interferon gamma release test. When an anti-tuberculosis treatment is indicated, monitoring should be performed to determine liver enzyme values with consideration of age as well as comorbid conditions such as a history of alcoholism, age, obesity, concomitant hepatotoxic drugs, and history of liver disease.Conclusion: Latent tuberculosis should be considered in patients with multiple sclerosis who are going to be treated with immunomodulatory and immunosuppressant medications. Transaminase level monitoring is required on a periodic basis depending on clinical and laboratory characteristics. In addition to the liver impairment, other side effects should be considered when Isoniazid is prescribed.
publishDate 2018
dc.date.created.spa.fl_str_mv 2018-01
dc.date.accessioned.none.fl_str_mv 2020-06-11T13:20:54Z
dc.date.available.none.fl_str_mv 2020-06-11T13:20:54Z
dc.type.eng.fl_str_mv article
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.spa.spa.fl_str_mv Artículo
dc.identifier.doi.none.fl_str_mv https://doi.org/10.1177/2055217317752202
dc.identifier.uri.none.fl_str_mv https://repository.urosario.edu.co/handle/10336/24625
url https://doi.org/10.1177/2055217317752202
https://repository.urosario.edu.co/handle/10336/24625
dc.language.iso.none.fl_str_mv eng
language eng
dc.relation.citationIssue.none.fl_str_mv No. 1
dc.relation.citationTitle.none.fl_str_mv Multiple Sclerosis Journal - Experimental Translational and Clinical
dc.relation.citationVolume.none.fl_str_mv Vol. 4
dc.relation.ispartof.spa.fl_str_mv Multiple Sclerosis Journal - Experimental Translational and Clinical, ISSN: , Vol.4, No.1 (2018-01); pp. 2055217317752202
dc.relation.uri.spa.fl_str_mv https://journals.sagepub.com/doi/pdf/10.1177/2055217317752202
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.acceso.spa.fl_str_mv Abierto (Texto Completo)
rights_invalid_str_mv Abierto (Texto Completo)
http://purl.org/coar/access_right/c_abf2
dc.format.mimetype.none.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Multiple Sclerosis Journal - Experimental Translational and Clinical
institution Universidad del Rosario
dc.source.instname.spa.fl_str_mv instname:Universidad del Rosario
dc.source.reponame.spa.fl_str_mv reponame:Repositorio Institucional EdocUR
repository.name.fl_str_mv Repositorio institucional EdocUR
repository.mail.fl_str_mv edocur@urosario.edu.co
_version_ 1818106681150668800